ReviewInternational journal of clinical and experimental pathology2013
Advances in distinguishing natural from induced Foxp3(+) regulatory T cells.
Review in International journal of clinical and experimental pathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised.Frontiers in medicine · 2020Pooled it
- Increased Foxp3Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Trial
- Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The Effects of In Utero HIV and Antiretroviral Therapy Exposure on Infant T-Cell and Monocyte Activation, Function, and Regulation of Immune-Modulatory Pathways.Mediators of inflammation · 2026Article
- Itreg cells Ameliorates MOG-induced brain inflammation via endowing DC tolerogenic capacity predominantly via TGF-beta signaling mediated AKT/mTOR pathway inhibition.Molecular medicine (Cambridge, Mass.) · 2025Article
- Peptides Derived from α-Tubulin Induce Functional T Regulatory Cells.International journal of molecular sciences · 2025Article
- Role of cell-based therapies in digestive disorders: Obstacles and opportunities.Regenerative therapy · 2025Review
- The Immunomodulatory Role of Regulatory T Cells in Preterm Birth and Associated Pregnancy Outcomes.International journal of molecular sciences · 2024Review
- Regulatory T Cell Dysfunction in Autoimmune Diseases.International journal of molecular sciences · 2024Review
- Lipid metabolism in tumor-infiltrating regulatory T cells: perspective to precision immunotherapy.Biomarker research · 2024Review
- Induced regulatory T cells remain suppressive capability on effector T cells and synovial fibroblasts in collagen-induced arthritis.Immunologic research · 2023Article
- Enhancing Regulatory T Cells to Treat Inflammatory and Autoimmune Diseases.International journal of molecular sciences · 2023Review
- Macrophage-derived exosome promotes regulatory T cell differentiation in malignant pleural effusion.Frontiers in immunology · 2023Article
- Histone deacetylase 6 plays an important role in TGF-β-induced murine Treg cell differentiation by regulating cell proliferation.Scientific reports · 2022Article
- Integrated single-cell transcriptomics of cerebrospinal fluid cells in treatment-naïve multiple sclerosis.Journal of neuroinflammation · 2022Article
- Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity.Journal of hematology & oncology · 2022Review
- Mesenchymal Stromal Cells from Healthy and Inflamed Human Gingiva Respond Differently toInternational journal of molecular sciences · 2022Article
- The Importance of the Transcription Factor Foxp3 in the Development of Primary Immunodeficiencies.Journal of clinical medicine · 2022Review
- Review
- Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
For more than a decade now, the regulatory T (Treg) cell has widely been considered as a critical subpopulation of T cells which can suppress effector T cell responses as well as suppressing the activity of other immune cells, such as mast cell, dendritic cells, and B cells. Treg cells have been broadly characterized as comprising of two main populations: thymus-derived natural Treg (nTreg) cells, and peripherally generated induced Treg (iTreg) cells. Both subsets have similar phenotypic characteristics and comparable suppressive function against T cell-mediated immune response and diseases. However, both Foxp3 positive Treg subsets exhibit some specific differences such as different mRNA transcripts and protein expression, epigenetic modification, and stability. These subtle differences reinforce the notion that they represent unique and distinct subsets. Accurately distinguishing iTregs from nTregs will help to clarify the biological features and contributions of each Treg subsets in peripheral tolerance, autoimmunity and tumor immunity. One difficult problem is that it has not been possible to distinguish iTregs from nTregs using surface markers until two recent articles were published to address this possibility. This review will focus on very recent advances in using molecular markers to differentiate these Treg subsets.
Indexed as
Identifiers
23329997PMC3544233What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.